HCAHealthcare · Medical Care FacilitiesThe 26 Wall Street analysts covering HCA Healthcare, Inc. hold a median 12-month price target of $486 — -4.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 3 Nov 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores HCA Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (92): The share price has been relatively steady.
Accruals (52): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HCA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −4.9% from it.
Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $381 → $468 |
| 30 Oct 2026 | RBC Capital | Maintains | Outperform | $496 → $521 |
| 29 Oct 2026 | Barclays | Maintains | Equal-Weight | $387 → $401 |
| 28 Oct 2026 | B of A Securities | Maintains | Neutral | $450 → $500 |
| 28 Oct 2026 | Baird | Maintains | Neutral | $393 → $409 |
| 28 Oct 2026 | Keybanc | Maintains | Overweight | $435 → $490 |
| 28 Oct 2026 | TD Cowen | Maintains | Buy | $460 → $486 |
| 12 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 12 Oct 2026 | TD Cowen | Maintains | Buy | $431 → $460 |
| 7 Oct 2026 | RBC Capital | Maintains | Outperform | $435 → $496 |
| 7 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 23 Sept 2026 | BMO Capital | Initiates | Outperform | — |
| 23 Sept 2026 | BMO Capital | Initiates | Outperform | $495 |
| 18 Sept 2026 | Leerink Partners | Maintains | Outperform | $492 |
| 18 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 8 Sept 2026 | RBC Capital | Reiterates | Outperform | — |
| 8 Sept 2026 | RBC Capital | Reiterates | Outperform | $435 |
| 20 Aug 2026 | JP Morgan | Maintains | Neutral | $490 → $425 |
| 20 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HCA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, HCA Healthcare, Inc. returned +9.0% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 45% of US stocks
Cheaper than 63% of US stocks
Cheaper than 99% of US stocks
Cheaper than 38% of US stocks
Higher than 36% of US stocks
Higher than 32% of US stocks
Higher than 55% of US stocks
Higher than 72% of US stocks
Higher than 67% of US stocks
Higher than 6% of US stocks
Higher than 95% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HCA Healthcare, Inc. has a market value of $97.7B and an enterprise value of $152.6B.
Revenue in the twelve months to 30 June 2026: $78.0B. The latest quarter grew 3.6% year on year.
Net income over the same four quarters: $7.9B, a 10.1% net margin.
Diluted earnings per share, trailing twelve months: $29.87.
Free cash flow in the twelve months to 30 June 2026: $6.0B.
HCA Healthcare, Inc. spent $8.7B on share buybacks and $682.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 15.5×; forward P/E: 15.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.67%, paying out 10% of earnings.
HCA Healthcare, Inc. employs 230,000 people — $339K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HCA Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Healthcare stocks, including hospital groups, jumped following the midterm results. The report says a bull-market case is developing.
Why it matters — HCA watchers may note the reported rise in hospital-group stocks after the midterm results.
MarketWatch reports that the Democratic victory in the midterm elections could benefit the nation’s largest hospitals, while drugmakers face scrutiny.
Why it matters — HCA watchers may note the report’s implication that the political outcome could be favorable for large hospital companies.
Zacks Investment Research explains that its Style Scores help investors find top-rated stocks based on their investing style, and presents why readers should use them in evaluating HCA Healthcare.
Why it matters — HCA watchers may find the article relevant as it discusses a Zacks tool for identifying stocks that fit an investor's style.
The headline says HCA Healthcare, Centene and Oscar are riding a “Blue Wave” to buy points. The excerpt notes that investors may be thinking ahead to 2028.
Why it matters — The item links HCA to a market trend involving buying points and possible investor attention to 2028.
The article discusses the U.S. vote and the stakes for control of Congress, including potential shifts in healthcare policy, energy incentives, and federal spending. It frames the election as relevant to investors assessing which companies could benefit from Washington's priorities.
Why it matters — HCA watchers may follow potential changes in healthcare policy and federal spending as Congress's control is decided.
The 26 Wall Street analysts covering HCA Healthcare, Inc. have a median 12-month price target of $486, with estimates ranging from $380 to $550. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 26 analysts covering HCA Healthcare, Inc., 15 rate it a Buy, 9 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks HCA Healthcare, Inc. 85 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, HCA Healthcare, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).
No one can know that. What the data says: the median 12-month target from 26 analysts implies -4.9% from the last close, and Ticker Nerd's factor model ranks HCA Healthcare, Inc. 85 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HCA Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $380 to $550 over the next 12 months.
HCA Healthcare, Inc. returned +9.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
HCA Healthcare, Inc. is a healthcare services company that operates a broad network of hospitals, ambulatory surgery centers, freestanding emergency rooms, urgent care clinics, physician practices, diagnostic and imaging centers, rehabilitation facilities, and other care sites.
The most recent item we track (Barrons, 4 Nov 2026): "Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing.". Healthcare stocks, including hospital groups, jumped following the midterm results. The report says a bull-market case is developing.
HCA Healthcare, Inc. is a healthcare services company that operates a broad network of hospitals, ambulatory surgery centers, freestanding emergency rooms, urgent care clinics, physician practices, diagnostic and imaging centers, rehabilitation facilities, and other care sites. The company serves patients across the United States and the United Kingdom, with a strong emphasis on general and acute care, outpatient services, and specialty care such as oncology and rehabilitation. HCA Healthcare also provides home health and hospice services in select markets, supporting care across multiple stages of treatment. As one of the largest private operators in the hospital sector, HCA Healthcare plays a central role in delivering integrated medical care through coordinated local facilities and physician relationships. Founded in 1968 and headquartered in Nashville, Tennessee, HCA Healthcare focuses on expanding access to community-based healthcare services through its diversified clinical network.
CEO Mr. Samuel N. Hazen · 230,000 employees · United States · https://www.hcahealthcare.com
